BRIDGEND, WALES – October 08, 2025 – Molomix Bioscience Ltd., a pioneering diagnostics company, today announced the signing of a Memorandum of Understanding (MoU) with global technology innovator SiGENEX and the prestigious School of Medicine at Cardiff University. This strategic alliance establishes a powerful framework for joint collaboration in the field of medical research, positioning Wales at the forefront of molecular analysis and multiomic diagnostic technology development.
The partnership will focus on advancing automated gene sequencing and molecular analysis across multiple sectors, including clinical diagnostics and translational research. Central to this collaboration is SiGENEX’s AI-driven digital microfluidics platform – a field-programmable system that fully automates and decentralises complex molecular and multi-omic workflows. By uniting cutting-edge automation with advanced bioinformatics, the platform delivers faster, more accurate, and more affordable insights at the point of need. This approach not only opens new possibilities for research and clinical adoption but also creates a scalable commercial model designed to transform global access to next-generation diagnostics.
“This partnership is a landmark moment for us and for the life sciences ecosystem in Wales,” said Stephen Pickett, CEO of Molomix Bioscience. “By combining SiGENEX’s groundbreaking technology with the world-class research expertise of Cardiff University, we can accelerate the deployment of molecular analytics and next-generation diagnostics. Our model is about providing this technology as a service, removing the barrier of expensive upfront procurement. This will not only speed up analysis and diagnostics but also significantly reduce the costs and risks associated with the use of distant, centralised labs. This collaboration is designed for the mutual commercial benefit of all parties, establishing a powerful new model for how industry and academia can partner to translate world-class research into real-world impact. It also creates a sustainable pathway for the University to diversify its income, ensuring its vital research can continue to thrive.”
“At SiGENEX, our mission is to remove the barriers to advanced genomic testing and make multi-omic insights accessible anywhere they are needed,” said Dr. Bohao Yao, Director of SiGENEX Oxford Ltd. “This partnership with Molomix and Cardiff University demonstrates how world-class research, cutting-edge technology, and innovative deployment models can come together to accelerate diagnostics and personalised medicine. By decentralising sequencing and molecular workflows, we are creating a pathway for faster, more precise, and more affordable healthcare solutions – not just in Wales, but globally.”
Prof Rachel Errington, Head of the School of Medicine at Cardiff University said “We are delighted to be working with Molomix and SiGENEX in developing an innovative platform technology which could have a major impact both as a research tool and in healthcare.”
The MoU outlines a formal structure for the three parties to jointly apply for research funding, exchange scientific materials, and publish findings, with specific projects to be agreed upon on a case-by-case basis. Molomix Bioscience will lead the commercial deployment in the UK and Europe of the technologies developed and validated through this partnership.
About Molomix Bioscience Ltd.
Molomix Bioscience is a UK-based biotechnology company with a mission to empower its partners to solve humanity’s most pressing scientific and health challenges. By deploying a revolutionary decentralised, AI-powered platform, Molomix brings the world’s most advanced molecular and multiomic technologies directly to the point-of-need, making them accessible and affordable through a disruptive “as a Service” approach.
About SiGENEX
SiGENEX is pioneering the next generation of clinical genomics and multi-omics innovation through its proprietary thin-film transistor (TFT) digital microfluidics (DMF) and AI-driven automation platform. By integrating rapid sample preparation, sequencing, and advanced bioinformatics into a single decentralised system, SiGENEX delivers end-to-end, sample-to-insight workflows at the point of need. The platform’s unique zero-CapEx deployment model removes barriers for hospitals, research centres, and clinics by making advanced genomics accessible, affordable, and scalable. Headquartered in Boston, with operations at Oxford University’s BioEscalator and a development hub in Kuala Lumpur, SiGENEX is building a global federated network of hospitals and research labs to accelerate diagnostics, personalised medicine, and large-scale biomarker discovery.
About Cardiff University School of Medicine
Cardiff University’s School of Medicine is a leading international centre for medical research and education. Dedicated to improving health and wellbeing, the school drives scientific advancements and translates research discoveries into tangible benefits for patients and society. Our researchers are involved in cutting edge science and world class research in the field of medicine. Our commitment to research excellence and impact is supported though strong research groups, working collaboratively with fellow academics, the NHS and the medical industry. Our key research highlights include: Cancer and Genetics, Infection and Immunity, Psychological Medicine and Clinical Neurosciences and Population Medicine.
Contact Information:
Stephen Pickett
Chief Executive Officer
Molomix Bioscience Ltd
Tel: +44 7825 022518
E-mail: [email protected]
Web: https://molomix.co.uk
– ENDS –